Charles King, MD
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $7,600 of the $9,211 with a category attached, or 82.5%. Laser Specialty Medical, LLC accounts for 82.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $3,696 and has fallen 92.2% since, to $288 in 2025.
Across 69 payments — averaging $133.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Laser Specialty Medical, LLC$8K
- Astellas Pharma US Inc$340
- AbbVie$244
- Myriad Genetic Laboratories, Inc.$227
- Sumitomo Pharma America, Inc.$192
- Tempus AI, Inc$118
- plus $490 from 15 others
Across 52 payments — averaging $5156.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$268K
What the payments were for
- Speaking & faculty fees$1251%
- Food & beverage$1,45816%
- Education$280%
- Ownership interest$7,60083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Laser Specialty Medical, LLC | 3 | $7,600 |
| Astellas Pharma US Inc | 11 | $340 |
| AbbVie(2 entities) | 13 | $244 |
| Myriad Genetic Laboratories, Inc. | 11 | $227 |
| Sumitomo Pharma America, Inc. | 4 | $192 |
| Tempus AI, Inc | 1 | $118 |
| Pfizer | 6 | $86 |
| Johnson & Johnson | 4 | $74 |
| Laborie Medical Technologies Corp. | 2 | $48 |
| Tolmar Pharmaceuticals, Inc. | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $35 |
| Dentsply IH Inc. | 2 | $34 |
| 180 Medical, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $27 |
| Urogen Pharma, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $16 |
| Blue Earth Diagnostics | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,211 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 137 | $128,440 |
| GemtesaVibegron | 40 | $48,452 |
| Tamsulosin Hcl | 551 | $8,036 |
| Finasteride | 463 | $6,471 |
| Trospium Chloride | 44 | $4,151 |
| Methenamine Hippurate | 37 | $3,425 |
| Potassium Citrate ErPotassium Citrate | 26 | $3,354 |
| Bicalutamide | 65 | $2,467 |
| Dutasteride | 46 | $2,091 |
| Testosterone Cypionate | 37 | $1,712 |
| Tadalafil | 15 | $1,017 |
| Estradiol | 18 | $1,004 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $623 |
| Terazosin Hcl | 22 | $454 |
| Alendronate Sodium | 31 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $340 | $128,440137 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $192 | $48,45240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Ocala
- Harvey TaubOcala$208K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.